Actinogen is a neurotherapeutics developer realizing a revolutionary therapy so neurology patients and their families can live their best lives

ACW receives $4.8m R&D tax incentive rebate

Actinogen announces that it has received a research and development (R&D) tax incentive rebate of $4,792,865 from the Australian Tax Office for the 2023 financial year.

XanaCIDD trial enrolment passes 50%

Actinogen announces that enrolment in its XanaCIDD Phase 2a trial comprising 160 participants with cognitive impairment associated with persistent major depressive disorder (MDD) now exceeds 50 percent (that is, more than 80 participants enrolled to date).

Results remain on track for Q2 CY2024.

Results of ACW 2023 AGM

Actinogen’s 2023 AGM was held 17 November 2023.

Resolutions 1 to 12 were passed on a poll, with Resolution 4 (Approval of increased 7.1A placement capacity), Resolution 11 (Approval to Amend Constitution – renewal of the Proportional Bid Provisions) and Resolution 12 (Approval to Amend Constitution – Employee share scheme provisions) being passed by a sufficient majority as special resolutions.

An amended constitution was also posted to the ASX platform and on the company’s website.

Click here to view Constitution.

ACW 2023 AGM – Chair’s address and CEO’s presentation

ACW  is pleased to release the Chair’s address and CEO’s slide presentation to the Annual General Meeting 17 November 2023

ACW CEO presents corporate overview at Bell Potter Healthcare Conference 2023

ACW’s CEO, Dr Steven Gourlay  presents an updated corporate overview at the Bell Potter Healthcare Conference.

Actinogen appoints William Souter as new CFO

ACW announces the appointment of Mr William (Will) Souter as full time Chief Financial Officer, commencing on 5 February 2024.